Formulations and treatment methods
AssigneeCamurus AB
InventorFredrik Tiberg
Life of this patent
Estimating the term…
Abstract
A lipid controlled-release formulation comprising: a) about 30 to about 50 wt % of at least one diacyl glycerol; b) about 30 to about 50 wt % of at least one phosphatidylcholine; c) about 5 to about 15 wt % ethanol; d) about 0.05 to about 0.5 wt % buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.
Claims14
A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment comprising a step of:
- administering a controlled-release formulation containing a dose of at least one opioid to said infant;
- wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration;
- wherein the at least one opioid is buprenorphine, and
- wherein the controlled-release formulation is a lipid controlled-release formulation comprising:
- a) about 30 to about 50 wt % of at least one diacyl glycerol;
- b) about 30 to about 50 wt % of at least one phosphatidylcholine;
- c) about 5 to about 15 wt % ethanol;
- and
- d) about 0.05 to about 0.5 wt % buprenorphine.
Dependencies are inferred from the claim text.